留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

超长效镇痛药物的研发与转化

贺渝淼 李默晗 马超 黄宇光

贺渝淼, 李默晗, 马超, 黄宇光. 超长效镇痛药物的研发与转化[J]. 协和医学杂志, 2024, 15(2): 251-257. doi: 10.12290/xhyxzz.2023-0574
引用本文: 贺渝淼, 李默晗, 马超, 黄宇光. 超长效镇痛药物的研发与转化[J]. 协和医学杂志, 2024, 15(2): 251-257. doi: 10.12290/xhyxzz.2023-0574
HE Yumiao, LI Mohan, MA Chao, HUANG Yuguang. Development and Translation of Super Long-acting Analgesics[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 251-257. doi: 10.12290/xhyxzz.2023-0574
Citation: HE Yumiao, LI Mohan, MA Chao, HUANG Yuguang. Development and Translation of Super Long-acting Analgesics[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 251-257. doi: 10.12290/xhyxzz.2023-0574

超长效镇痛药物的研发与转化

doi: 10.12290/xhyxzz.2023-0574
基金项目: 

中央高水平医院临床科研专项 2022-PUMCH-C-067

详细信息
    通讯作者:

    马超, E-mail:machao@ibms.cams.cn

    黄宇光, E-mail:garypumch@163.com

  • 中图分类号: R614;R364

Development and Translation of Super Long-acting Analgesics

Funds: 

National High Level Hospital Clinical Research Funding 2022-PUMCH-C-067

More Information
  • 摘要: 疼痛管理越来越受到临床医生的重视,疼痛也因此被列为第五大生命体征。传统镇痛药物作用时间有限,疼痛早期需密切监测、频繁用药才能降低慢性疼痛发生率,并达到满意的镇痛效果。因此,如何延长镇痛药物的作用时间成为疼痛领域的重要研究方向。从使用佐剂、开发衍生药物,到缓释药物载体的引进,超长效镇痛药物研发进程被不断推进,其临床应用亦逐渐成为现实。本文简述超长效镇痛药物研发策略,并以缓释镇痛药物为重点,介绍缓释药物载体在镇痛领域的研发进展及产品转化现状,以期为超长效镇痛药物后续研究提供参考。
    作者贡献:贺渝淼、李默晗负责查阅文献、论文撰写及修订;马超、黄宇光负责选题设计、论文审校。
    利益冲突:所有作者均声明不存在利益冲突
  • 图  1  癸二酰双那布扶林酯化学结构示意图

    Figure  1.  The chemical structure of dinalbuphine sebacate

    图  2  脂质体结构示意图

    A.单层脂质体(单囊脂质体);B.多层脂质体;C.多囊脂质体

    Figure  2.  The structural illustrations of liposome

    A. unilamellar liposome; B. multilamellar liposome; C. multivesicular liposome

    图  3  多聚体结构及形态示意图

    A.聚乳酸羟基乙酸;B.纳米颗粒;C.纳米纺丝;D.纳米凝胶

    Figure  3.  The morphological illustrations of polymers

    A. PLGA; B. nanoparticle; C. nanofiber; D. nanogel

  • [1] Queremel Milani D A, Davis D D. Pain management medications[M/OL]//Anon. StatPearls [Internet]. Treasure Island: StatPearls Publishing, 2023[2023-11-20]. https://www.ncbi.nlm.nih.gov/books/NBK560692/.
    [2] Yeh C Y, Jao S W, Chen J S, et al. Sebacoyl dinalbuphine ester extended-release injection for long-acting analgesia: a multicenter, randomized, double-blind, and placebo-controlled study in hemorrhoidectomy patients[J]. Clin J Pain, 2017, 33(5): 429-434. doi:  10.1097/AJP.0000000000000417
    [3] Lumosa Therapeutics. LT1001 extended release analgesic injection [EB/OL]. [2023-11-20]. https://www.lumosa.com.tw/en/pipeline/edit/1.
    [4] Aungst B J, Myers M J, Shefter E, et al. Prodrugs for improved oral nalbuphine bioavailability: inter-species differences in the disposition of nalbuphine and its acetylsalicylate and anthranilate esters[J]. Int J Pharm, 1987, 38(1/3): 199-209.
    [5] Huang J F, Sung K C, Hu O Y P, et al. The effects of electrically assisted methods on transdermal delivery of nalbuph-ine benzoate and sebacoyl dinalbuphine ester from solutions and hydrogels[J]. Int J Pharm, 2005, 297(1/2): 162-171.
    [6] 刘欢. 2.5亿元!四川大学华西医院签订2项技术合同联合开发麻醉新药[EB/OL]. (2020-06-15)[2023-11-20]. https://www.wchscu.cn/comprehensive/52075.html.

    Liu H. 250 Million yuan! Sichuan University West China Hospital signs two technical contracts to jointly develop new anesthetic drugs[EB/OL]. (2020-06-15)[2023-11-20]. https://www.wchscu.cn/comprehensive/52075.html.
    [7] 刘进, 柯博文, 张文胜, 等. 一种季铵盐类化合物及其制备方法与用途: CN201910100568.3[P]. 2019-08-23.

    Liu J, Ke B W, Zhang W S, et al. A quaternary ammonium salt compound and its preparation method and application: CN201910100568.3[P]. 2019-08-23.
    [8] 柯博文, 刘进, 张文胜, 等. 一种季铵盐类化合物及其制备方法与用途: CN202010071506.7[P]. 2020-05-15.

    Ke B W, Liu J, Zhang W S, et al. A quaternary ammonium salt compound and its preparation method and application: CN202010071506.7[P]. 2020-05-15.
    [9] Allen D, Hanumantharao S N, McDonell R, et al. Preclini-cal characterization of the efficacy and safety of biologic N-001 as a novel pain analgesic for post-operative acute pain treatment[J]. Sci Rep, 2023, 13(1): 11778. doi:  10.1038/s41598-023-38618-4
    [10] Chareancholvanich K, Tantithawornwat S, Ruangsomboon P, et al. Efficacy of epinephrine in local infiltration analgesia on pain relief and opioid consumption following total knee arthroplasty: a randomized controlled trial[J]. Acta Orthop, 2023, 94: 97-101. doi:  10.2340/17453674.2023.8482
    [11] Li F Z, Guo L, Huang Z J, et al. Effects of dexmedeto-midine as an adjuvant to ropivacaine or ropivacaine alone on duration of postoperative analgesia: a systematic review and meta-analysis of randomized controlled trials[J]. PLoS One, 2023, 18(10): e0287296. doi:  10.1371/journal.pone.0287296
    [12] Wei X M, Liu Z, Lv L C, et al. Comparison of dexmedetomidine and dexamethasone as adjuvants to the ultrasound-guided interscalene nerve block in arthroscopic shoulder surgery: a systematic review and Bayesian network meta-analysis of randomized controlled trials[J]. Front Med (Lausanne), 2023, 10: 1159216.
    [13] Bailard N S, Ortiz J, Flores R A. Additives to local anesthetics for peripheral nerve blocks: evidence, limitations, and recommendations[J]. Am J Health Syst Pharm, 2014, 71(5): 373-385. doi:  10.2146/ajhp130336
    [14] Racle J P, Jourdren L, Benkhadra A, et al. Effect of adding sodium bicarbonate to bupivacaine for spinal anesthesia in elderly patients[J]. Anesth Analg, 1988, 67(6): 570-573.
    [15] Balocco A L, Van Zundert P G E, Gan S S, et al. Extended release bupivacaine formulations for postoperative analgesia: an update[J]. Curr Opin Anaesthesiol, 2018, 31(5): 636-642. doi:  10.1097/ACO.0000000000000648
    [16] Finneran J J 4th, Ilfeld B M. Continuous peripheral nerve blocks for analgesia following painful ambulatory surgery: a review with focus on recent developments in infusion technology[J]. Curr Opin Anaesthesiol, 2023, 36(5): 525-532. doi:  10.1097/ACO.0000000000001284
    [17] Nicolotti D, Iotti E, Fanelli G, et al. Perineural catheter infection: a systematic review of the literature[J]. J Clin Anesth, 2016, 35: 123-128. doi:  10.1016/j.jclinane.2016.07.025
    [18] He Y M, Qin L N, Huang Y G, et al. Advances of nano-structured extended-release local anesthetics[J]. Nanoscale Res Lett, 2020, 15(1): 13. doi:  10.1186/s11671-019-3241-2
    [19] Lin W F, Goldberg R, Klein J. Poly-phosphocholination of liposomes leads to highly-extended retention time in mice joints[J]. J Mater Chem B, 2022, 10(15): 2820-2827. doi:  10.1039/D1TB02346B
    [20] Malige A, Pellegrino A N, Kunkle K, et al. Liposomal bupivacaine in adductor canal blocks before total knee arthroplasty leads to improved postoperative outcomes: a randomized controlled trial[J]. J Arthroplasty, 2022, 37(8): 1549-1556. doi:  10.1016/j.arth.2022.03.073
    [21] Ilfeld B M, Eisenach J C, Gabriel R A. Clinical effective-ness of liposomal bupivacaine administered by infiltration or peripheral nerve block to treat postoperative pain[J]. Anesthesiology, 2021, 134(2): 283-344. doi:  10.1097/ALN.0000000000003630
    [22] Nguyen A, Grape S, Gobbetti M, et al. The postoperative analgesic efficacy of liposomal bupivacaine versus long-acting local anaesthetics for peripheral nerve and field blocks: a systematic review and meta-analysis, with trial sequential analysis[J]. Eur J Anaesthesiol, 2023, 40(9): 624-635. doi:  10.1097/EJA.0000000000001833
    [23] 中国科学院过程工程研究所. 国内首个长效镇痛类均一粒径微球缓释制剂获临床批件[EB/OL]. (2022-01-12)[2023-11-20]. https://ipe.cas.cn/xwdt_/kyjz/202201/t20220112_6339476.html.

    Institute of Process Engineering, Chinese Academy of Sciences. The first domestically produced long-acting analgesic uniformly sized microsphere sustained-release formulation has received clinical approval[EB/OL]. (2022-01-12)[2023-11-20]. https://ipe.cas.cn/xwdt_/kyjz/202201/t20220112_6339476.html.
    [24] 绿叶制药集团. 国内首个罗哌卡因多囊脂质体创新制剂即将进入临床, 有望实现长效缓释镇痛、提升用药安全性[EB/OL]. (2021-03-08)[2023-11-20]. https://www.luye.cn/lvye/view.php?id=1314.

    Luye Pharma. The first domestic innovative formulation of ropivacaine liposomes is about to enter clinical practice, which is expected to achieve long-term sustained release analgesia and improve medication safety[EB/OL]. (2021-03-08)[2023-11-20]. https://www.luye.cn/lvye/view.php?id=1314.
    [25] Wang T, Hurwitz O, Shimada S G, et al. Anti-nociceptive effects of bupivacaine-encapsulated PLGA nanoparticles applied to the compressed dorsal root ganglion in mice[J]. Neurosci Lett, 2018, 668: 154-158. doi:  10.1016/j.neulet.2018.01.031
    [26] He Y M, Qin L N, Fang Y H, et al. Electrospun PLGA nanomembrane: a novel formulation of extended-release bupivacaine delivery reducing postoperative pain[J]. Mater Des, 2020, 193: 108768. doi:  10.1016/j.matdes.2020.108768
    [27] Pacira Pharmaceuticals. EXPAREL|Non-opioid analgesic pain management[EB/OL]. [2023-11-20]. https://www.exparel.com/.
    [28] Zhang Y J, Shi K, Yang X, et al. Sustained release of levobupivacaine from temperature-sensitive injectable hydrogel for long-term local anesthesia in postoperative pain management[J]. Biomaterials, 2023, 299: 122129. doi:  10.1016/j.biomaterials.2023.122129
    [29] Ji T J, Li Y, Deng X R, et al. Delivery of local anaesthetics by a self-assembled supramolecular system mimicking their interactions with a sodium channel[J]. Nat Biomed Eng, 2021, 5(9): 1099-1109. doi:  10.1038/s41551-021-00793-y
    [30] Innocoll Biotherapeutics. FDA approves XARACOLL® (bupivacaine HCl) implant, a non-opioid, drug-device treatment option for acute postsurgical pain relief for up to 24 hours following open inguinal hernia repair in adults[EB/OL]. [2023-11-20]. https://www.innocol..com/news-and-media/2020/08/fda-approves-xaracoll-bupivacaine-hcl-impl-ant-a-non-opioid-drug-device-treatment-option-for-acute-post-surgical-pain-relief-for-up-to-24-hours-following-open-inguinal-hernia-repair-in-adults/.
    [31] Ekelund A, Peredistijs A, Grohs J, et al. SABER-bupivacaine reduces postoperative pain and opioid consumption after arthroscopic subacromial decompression: a randomized, placebo-controlled trial[J]. J Am Acad Orthop Surg Glob Res Rev, 2022, 6(5): e21.00287.
    [32] Innocoll Pharmaceuticals Limited. How it works-SABER technology|POSIMIR® [EB/OL]. [2023-11-20]. https://posimir.com/technology/.
    [33] Guo W, Cao D L G, Rao W H, et al. Achieving long-acting local analgesia using an intelligent hydrogel encapsulated with drug and pH regulator[J]. ACS Appl Mater Interfaces, 2023, 15(36): 42113-42129. doi:  10.1021/acsami.3c03149
    [34] Zhang W J, Xu W G, Ning C, et al. Long-acting hydrogel/microsphere composite sequentially releases dexmedetomid-ine and bupivacaine for prolonged synergistic analgesia[J]. Biomaterials, 2018, 181: 378-391. doi:  10.1016/j.biomaterials.2018.07.051
    [35] He Y M, Sun F R, Li M H, et al. A gel/fiber composite formulation achieves sequential delivery based on multimodal analgesia reducing chronic pain[J]. Mater Des, 2023, 225: 111541. doi:  10.1016/j.matdes.2022.111541
    [36] Li M H, He Y M, Liu Z R, et al. Construction of meloxicam and bupivacaine co-delivery nanosystem based on the pathophysiological environment of surgical injuries for enhanced postoperative analgesia[J]. Nano Res, 2023, 16(12): 13301-13308. doi:  10.1007/s12274-023-6074-3
    [37] Heller J, Barr J. Biochronomer technology[J]. Expert Opin Drug Deliv, 2005, 2(1): 169-183. doi:  10.1517/17425247.2.1.169
    [38] Blair H A. Bupivacaine/meloxicam prolonged release: a review in postoperative pain[J]. Drugs, 2021, 81(10): 1203-1211. doi:  10.1007/s40265-021-01551-9
    [39] Heron Therapeutics. ZYNRELEF® [EB/OL]. [2023-11-20]. https://www.herontx.com/product-portfolio/zynrelef/.
  • 加载中
图(3)
计量
  • 文章访问数:  1181
  • HTML全文浏览量:  21
  • PDF下载量:  27
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-11-29
  • 录用日期:  2023-12-29
  • 网络出版日期:  2024-02-20
  • 刊出日期:  2024-03-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!